Characteristics and Survival Outcomes Related to the Infra-pyloric Lymph Node Status of Gastric Cancer Patients
Overview
Oncology
Authors
Affiliations
Background: To study metastasis to the infra-pyloric (no. 6) lymph nodes and their subgroups and the related risk factors of gastric cancer patients.
Methods: Gastric cancer patients who underwent gastrectomy with complete postoperative pathological information on the no. 6 lymph node station and its subgroups from January 1, 2008, to December 31, 2011, were included. The clinicopathological characteristics and survival outcomes were analyzed.
Results: A total of 121 patients were included; they had 6.1 ± 7.7 positive lymph nodes, and 35.1 ± 14.2 lymph nodes were examined. The overall lymph node positivity rate was 67.8% (82/121) with a positivity rate of 28.1% (34/121) for the no. 6 lymph nodes. The metastasis rate was 6.6% for the no. 6a nodes, 6.6% for the no. 6b nodes, and 21.5% for the no. 6c nodes. Also, no. 8a (OR = 1.329, p = 0.017) and no. 9 (OR = 1.250, p = 0.022) nodal positivity and lower third tumor location (OR = 1.278, p = 0.001) were independent risk factors for no. 6 lymph nodal metastasis. There was a significant survival difference between patients with positive and negative no. 6 lymph nodes and patients with metastasis to other lymph node stations (p < 0.001).
Conclusions: Patients with no. 6 lymph node metastasis have poor survival outcomes. Complete infra-pyloric lymphadenectomy is necessary and crucial for gastric cancer patients.
Ursu S, Ciocan A, Ursu C, Gherman C, Ciocan R, Pop R Diagnostics (Basel). 2023; 13(22).
PMID: 37998537 PMC: 10670422. DOI: 10.3390/diagnostics13223401.
Pang H, Zhang W, Liang X, Zhang Z, Chen X, Zhao L Adv Ther. 2021; 38(9):4917-4934.
PMID: 34379305 DOI: 10.1007/s12325-021-01870-z.
Yang K, Zhang W, Liu K, Chen X, Chen X, Zhou Z BMC Surg. 2021; 21(1):216.
PMID: 33902530 PMC: 8077741. DOI: 10.1186/s12893-021-01192-5.
Discovering Biomarkers in Peritoneal Metastasis of Gastric Cancer by Metabolomics.
Pan G, Ma Y, Suo J, Li W, Zhang Y, Qin S Onco Targets Ther. 2020; 13:7199-7211.
PMID: 32801750 PMC: 7394602. DOI: 10.2147/OTT.S245663.
Yang W, Wu B, Ma N, Wang Y, Guo J, Zhu J In Vitro Cell Dev Biol Anim. 2019; 55(6):445-452.
PMID: 31140101 DOI: 10.1007/s11626-019-00360-5.